Showing 11-20 of 1858 results for "".
- June 2024 - ISSUEShttps://practicaldermatology.com/issues/june-2024/
- July 2024 - ISSUEShttps://practicaldermatology.com/issues/july-2024/
- January/February 2025 - ISSUEShttps://practicaldermatology.com/issues/january-february-2025/
- May/June 2025 - ISSUEShttps://practicaldermatology.com/issues/may-june-2025/
What You Missed at San Diego Dermatology Symposium
https://practicaldermatology.com/topics/psoriasis/what-you-missed-at-san-diego-dermatology-symposium/19884/Jashin Wu, MD, founder of San Diego Dermatology Symposium, gives an overview of the 2020 meeting, which went virtual.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availExploring the Complexities of Psoriasis
https://practicaldermatology.com/topics/psoriasis/exploring-the-complexities-of-psoriasis/18553/Biologic therapies developed over the last decade or more to treat psoriasis may do more than clear the skin. Researchers are investigating the effects of treatment on comorbid risks, and comparing treatment with older interventions. Jashin Wu, MD explains.